- Home
- FATE
as 07-26-2024 4:00pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 418.9M | IPO Year: | 2013 |
| Target Price: | $6.85 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.63 - $8.83 | Next Earning Date: | 08-06-2024 |
| Revenue: | $6,478,000 | Revenue Growth: | -95.27% |
| Revenue Growth (this year): | -92.56% | Revenue Growth (next year): | -26.88% |
Stock Insider Trading Activity of Fate Therapeutics Inc. (FATE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dulac Edward J III | FATE | Chief Financial Officer | Mar 4 '24 | Sell | $7.77 | 2,447 | $19,013.19 | 101,479 | SEC Form 4 |
| Dulac Edward J III | FATE | Chief Financial Officer | Jan 29 '24 | Sell | $5.00 | 1,849 | $9,245.00 | 103,926 | SEC Form 4 |
| Valamehr Bahram | FATE | Chief R&D Officer | Jan 9 '24 | Sell | $4.38 | 11,271 | $49,366.98 | 158,069 | SEC Form 4 |
| Wolchko J Scott | FATE | President and CEO | Jan 9 '24 | Sell | $4.37 | 14,391 | $62,888.67 | 371,248 | SEC Form 4 |
| TAHL CINDY | FATE | General Counsel and Secretary | Jan 9 '24 | Sell | $4.37 | 10,874 | $47,519.38 | 142,361 | SEC Form 4 |
| Dulac Edward J III | FATE | Chief Financial Officer | Jan 9 '24 | Sell | $4.37 | 7,028 | $30,712.36 | 105,775 | SEC Form 4 |
| Dulac Edward J III | FATE | Chief Financial Officer | Jan 2 '24 | Sell | $3.66 | 5,182 | $18,966.12 | 112,803 | SEC Form 4 |
| Redmile Group, LLC | FATE | Director10% Owner | Dec 26 '23 | Buy | $3.72 | 44,630 | $166,023.60 | 13,180,388 | SEC Form 4 |
| Dulac Edward J III | FATE | Chief Financial Officer | Dec 18 '23 | Sell | $3.50 | 1,585 | $5,547.50 | 117,985 | SEC Form 4 |
| TAHL CINDY | FATE | General Counsel and Secretary | Nov 9 '23 | Sell | $2.40 | 24,363 | $58,471.20 | 153,235 | SEC Form 4 |
Latest Fate Therapeutics Inc. News
FATE Breaking Stock News: Dive into FATE Ticker-Specific Updates for Smart Investing
Motley Fool
6 days ago
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
GlobeNewswire
24 days ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Piper Sandler Upgrades Fate Therapeutics to Overweight From Neutral, Adjusts Price Target to $6 From $4
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
Compare FATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.